PharmaResources Shanghai Co Ltd
SZSE:301230
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (41.3), the stock would be worth ¥44.01 (3% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 40.2 | ¥42.9 |
0%
|
| 3-Year Average | 41.3 | ¥44.01 |
+3%
|
| 5-Year Average | 36.3 | ¥38.73 |
-10%
|
| Industry Average | 20.1 | ¥21.38 |
-50%
|
| Country Average | 20.8 | ¥22.19 |
-48%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
P
|
PharmaResources Shanghai Co Ltd
SZSE:301230
|
5.9B CNY | 40.2 | 161.3 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
958.5B USD | 1 647.2 | 3 973.8 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.9B USD | 25.5 | 25.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
127.8B USD | 21.4 | 34.1 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 36.2 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
299.9B CNY | 15.5 | 15.7 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.5B CHF | 31.4 | -120.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 24.4 | 25.2 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.4B USD | 45.6 | 45.8 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.8B USD | 14.9 | 20.5 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 29.1 | 29.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.5 |
| Median | 20.8 |
| 70th Percentile | 39.2 |
| Max | 266 666.7 |
Other Multiples
PharmaResources Shanghai Co Ltd
Glance View
PharmaResources Shanghai Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Shanghai, Shanghai and currently employs 983 full-time employees. The company went IPO on 2022-11-01. PharmaResources Shanghai Co Ltd is a China-based company mainly engaged in the development and commercial production of new drugs. The firm's main businesses include drug discovery, process research and development and commercial manufacturing business. The drug discovery business includes medicinal chemistry, synthetic chemistry and pharmacokinetics. The process research and development business includes process chemistry and process development as well as bulk drug research. The commercial manufacturing business includes customized manufacturing of new drugs and the research and development, production and sales of proprietary generic drug products. The firm distributes its products to the United States, India and other countries.
